Weeks after deciding to cut one of its 27 institutes and centers, the National Institutes of Health (NIH) is now seeking to create a new center focused on translational medicine. An advisory board will vote on the proposal next week.
According to the slides of November 1 Teleconference Advisory Board 10, the new center would benefit the increasing number of potential "targets" drug emerge basic research laboratories at the same time that pharmaceutical companies reduce research and development. The center's goal is to "develop and increase the effort of the organization in the development of new therapies."
It would house several existing programs at NIH, including a small-molecule screening program, a effort to develop drugs for rare and neglected diseases, and clinical and translational NIH Awards, which are large grants to support clinical research in academic medical centers. the center would also fold in the network acceleration Cures, a development program medicines created by the proposed health care reform law. It would have intramural close ties clinical center of the NIH, one, 240 underused facilities beds that advisers say NIH should open to external scientists.
the proposal for the translation Centre is a working group of the Council of scientific management review of the NIH (SMRB), which is seeking ways to streamline the structure of NIH. The NIH Director Francis Collins grew with a recent SMRB recommendation to combine research at the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism in a new addiction institute . This will balance 27 NIH Institutes to 26.
Added more institutes did not consider what some would SMRB. But the law creating SMRB also capped the total number of NIH institutes to 27, leaving open the possibility of creating a new one each time the number decreases.
The SMRB working group chair, Arthur Rubenstein, Dean of the University of Pennsylvania School of Medicine, did not respond to an email seeking comment before a meeting on December 7 in which full SMRB review the project center. But the debate can be expected. In the past, industry scientists have questioned the value of some of NIH's drug discovery efforts.
0 Komentar